Indoco Remedies’ AnaCipher Wins ANVISA Approval in Brazil
The Indoco Remedies AnaCipher ANVISA approval lets the Hyderabad CRO run bioequivalence studies for Brazil. What it covers and what is undisclosed.
FDA Issues Early Alert for B. Braun Dialysis Bloodline Sets Over Connector Risk
The B. Braun Streamline Bloodline Set FDA alert covers three lots of one model over a connector bonding flaw. Here is what is known.
Novartis Takes $1.9 Billion Write-Down After Rare-Disease Drug Trial Setback
The Novartis Q3 2026 results show a $1.9 billion del-desiran impairment yet a raised outlook. Here is how the three fit together.
Indira IVF Sabine Acquisition: Talks for a ₹1,300 Crore Deal
The Indira IVF Sabine acquisition is reportedly in advanced talks at up to Rs 1,300 crore for a 70-75% stake. What is known and not yet confirmed.
Bon Secours Surgery Partners Acquisition: Deal Signed at $5.7 Billion
The Bon Secours Surgery Partners acquisition is signed: USD 23.50 a share, a 64% premium and about USD 5.7 billion enterprise value.
FDA Alzheimer’s Prevention Initiative: NAIN Launches With New Accelerator
The FDA Alzheimer’s prevention initiative is the first project of NAIN, a new neuroscience programme. What it covers and what it does not do.
Uganda Ebola Travel Restrictions: 21-Day Quarantine for Returning Citizens
The Uganda Ebola travel restrictions require 21 days of quarantine for citizens returning from Congo, plus tighter screening and locator forms.
Nigeria Ebola Case Investigation: Africa CDC Probes Possible Kenya Link
The Nigeria Ebola case investigation begins as Africa CDC sends experts to test a possible Kenya link. What sequencing shows and does not show.
J&J JNJ-6143 Prostate Cancer Trial: 77% PSA Response in Early Study
The J&J JNJ-6143 prostate cancer pill cut PSA by 50% or more in 77% of patients in a Phase 1 trial. Data, safety and why reported figures differ.
AstraZeneca Stomach Cancer Drug Trial: 53% Lower Death Risk, But PFS Misses
The AstraZeneca stomach cancer drug trial showed a 53% lower risk of death in later-line patients, but progression-free survival missed significance.